6 unknown, 4 recruiting, 2 terminated, 1 active not recruiting. 10 Phase 2, 2 Phase 1, 1 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Unknown 4, Recruiting 3, Terminated 2, Not yet recruiting 1 |
| Phase 1 | 2 | Unknown 2 |
| Not applicable | 1 | Unknown 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Pembrolizumab: new trials by email Literature Review of Pembrolizumab trials Research Report on Pembrolizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma Zanzalintinib, Pembrolizumab - Phase 2, Zanzalintinib | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 20 | 2026-04-14 | 2026-08-20 |
| Neoadjuvant Immunotherapy and Organ-sparing Treatment in Patients With Stage I-III dMMR Colon Cancer 1 Cycle of Pembrolizumab, 2 Cycles of Pembrolizumab, 3 Cycles of Pembrolizumab - DMMR Colorectal Cancer, Colon Cancer Stage I | Phase 2 | Not yet recruiting | Ismail Gögenur | 152 | 2026-03-01 | 2026-02-20 |
| Phase II Study of Weekly Paclitaxel/Nab-Paclitaxel, Pembrolizumab, and Mirabegron for Recurrent Ovarian Cancer Weekly Paclitaxel/Nab-Paclitaxel, Pembrolizumab, and Mirabegron - Ovarian Cancer, Immunotherapy | Phase 2 | Recruiting | Obstetrics & Gynecology Hospital of Fudan University | 20 | 2025-12-01 | 2025-12-19 |
| Phase II Study of Moderate-dose Hypofractionated RT Combined With Pembrolizumab for HCC With Diffuse Tumor Thrombosis Moderate-dose Hypofractionated Intensity-modulated Radiotherapy, Pembrolizumab - Hepatocellular Carcinoma, Radiotherapy | Phase 2 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 30 | 2024-05-01 | 2024-04-29 |
| Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC Pembrolizumab, Cisplatin, Carboplatin - Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy | Phase 3 | Recruiting | Beijing Tongren Hospital | 272 | 2023-05-01 | 2023-10-30 |
| Impact of Immuno-Oncologic Agent on Neoadjuvant Chemotherapy in Triple Negative Breast Cancer Visium, Whole Genome Sequencing(WGS)/Whole Transcriptome Sequencing(WTS) - Triple Negative Breast Cancer, Neoadjuvant Chemotherapy | Unknown | Samsung Medical Center | 50 | 2023-03-02 | 2023-06-20 | |
| Phase Ib/II Trial of Combining Pembrolizumab and Lenvatinib With SBRT for HCC Patients With Portal Vein Thrombosis. Lenvatinib/Pembrolizumab plus SBRT combinations - Unresectable Hepatocellular Carcinoma, Pembrolizumab | Phase 1 / Phase 2 | Unknown | National Taiwan University Hospital | 27 | 2023-03-01 | 2023-03-02 |
| The Study Collect Clinical Data From the Treatment of Liver Cancer With New Drugs After 2019 and Integrate Biochemical and Pathological Indicators to Analyze Prognostic Outcomes, Including Overall Survival, Progression-free Survival, and Complications. Liver Cancer, Pembrolizumab | Active not recruiting | National Taiwan University Hospital | 2500 | 2023-01-31 | 2025-11-18 | |
| Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC Sitravatinib, Pembrolizumab - Carcinoma, Non-Small-Cell Lung, Lung Diseases | Phase 2 | Terminated | Sarah Goldberg | 9 | 2022-02-10 | 2025-04-17 |
| Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma Pembrolizumab, Lenvatinib - Melanoma, Renal Cell Carcinoma | Phase 2 | Terminated | Yale University | 18 | 2022-02-09 | 2026-06-04 |
| Pembrolizumab in Post Radical Operation ESCC Patients With Lymph Node Positive ( KEYSTONE-004 ) Pembrolizumab Injection [Keytruda] - ESCC, Adjuvant Treatment | Phase 2 | Unknown | Tianjin Medical University Cancer Institute and Hospital | 82 | 2021-05-01 | 2021-04-28 |
| A Study With Pembrolizumab for Non-small Cell Lung Cancer (NSCLC) A) Standard maintenance programme group, pembrolizumab 200mg, every 3 weeks, for a total of 2 years of follow-up and follow-up for 1 year;, B) Improvement maintenance programme group, pembrolizumab 200mg, every 6 weeks, for a total of 2 years of follow-up and 1 year follow-up; - Non-small-lung-cell Cancer, NSCLC, Pembrolizumab | Not applicable | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 216 | 2021-04-01 | 2020-11-30 |
| Pembrolizumab Plus Neoadjuvant Chemotherapy for Locally Advanced EGJ Adenocarcinoma Pembrolizumab Injection [Keytruda] - Adenocarcinoma of Esophagogastric Junction, Neoadjuvant Chemotherapy | Phase 2 | Unknown | Tianjin Medical University Cancer Institute and Hospital | 30 | 2021-04-01 | 2021-03-24 |
| Analysis of Gut Microbiota in Patients With Brain Metastasis of Non-small Cell Lung Cancer Treated by Pembrolizumab Combined With Chemotherapy Pembrolizumab Combined With Chemotherapy - Gut Microbiota, NSCLC | Phase 1 / Phase 2 | Unknown | Xiaorong Dong | 40 | 2020-04-01 | 2020-04-03 |
Carcinoma, Non-Small-Cell Lung (2) · Brain Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Renal Cell (1) · Colonic Neoplasms (1) · Liver Neoplasms (1) · Lung Diseases (1) · Lung Neoplasms (1) · Melanoma (1) · Neoplasm Metastasis (1) · Ovarian Neoplasms (1) · Sarcoma (1) · Squamous Cell Carcinoma of Head and Neck (1) · Triple Negative Breast Neoplasms (1)
Neoplasms (10) · Neoplasms by Site (9) · Neoplasms by Histologic Type (4) · Carcinoma (3) · Digestive System Diseases (3) · Digestive System Neoplasms (3) · Neoplasms, Glandular and Epithelial (3) · Adenocarcinoma (2) · Bronchial Neoplasms (2) · Carcinoma, Bronchogenic (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Liver Diseases (2) · Respiratory Tract Diseases (2) · Respiratory Tract Neoplasms (2)
pembrolizumab (11) · Cisplatin (2) · Fluorouracil (2) · lenvatinib (2) · Carboplatin (1) · Docetaxel (1) · Drug Therapy (1) · Taxes (1) · mirabegron (1) · nedaplatin (1) · sitravatinib (1)
National Taiwan University Hospital (2) · Tianjin Medical University Cancer Institute and Hospital (2) · Beijing Tongren Hospital (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Ismail Gögenur (1) · M.D. Anderson Cancer Center (1) · Obstetrics & Gynecology Hospital of Fudan University (1) · Samsung Medical Center (1) · Sarah Goldberg (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · Xiaorong Dong (1) · Yale University (1)
China (6) · United States (3) · Taiwan (2) · Denmark (1) · South Korea (1)
Chia-Hsien Cheng (1) · Dingzhi Huang, MD, PhD (1) · Fen Lan (1) · Harriet Kluger, MD (1) · Michael S Nakazawa, MD (1) · Sarah Goldberg, MD MPH (1) · Zhigang Huang (1)